Table 3.

Prognostic factors of overall survival and progression-free survival among RCC patients treated with ipilimumab plus nivolumab according to Cox model.

Patient Characteristics	Cox Proportional Hazards Regression for Survival
		Overall Survival					Progression-Free Survival
		12 Months OS, % (95% CI)	Unadjusted Analysis		Adjusted Analysis		6 Months PFS, % (95%CI)	Unadjusted Analysis		Adjusted Analysis
	N (%)		HR (95%CI)	p	HR (95%CI)	p		HR (95%CI)	p	HR (95%CI)	p
Age NA = 0
<70	25 (69%)	80.5 (64.8–100)	REF 1.3 (0.4–4.4)	0.66	NI	NI	63.0 (46.4–85.6)	REF 1.3 (0.5–3.2)	0.55	NI	NI
≥70	11 (31%)	57.7 (35.0–95.0)					62.3 (38.9–99.9)
PS ≥ 2 (%) NA = 0
No	32 (89%)	78.2 (63.9–95.7)	REF 7.2 (1.8–29.7)	0.0061	REF 1.8 (0.25–12.8)	0.57	70.8 (56.4–88.9)	REF 6.9 (2.0–23.0)	0.0018	REF 1.5 (0.30–8.0)	0.61
Yes	4 (11%)	NA					NA
≥3 metastatic site (%) NA = 0
No	23 (64%)	80.5 (64.8–100)	REF 2.5 (0.8–7.9)	0.12	NI	NI	68.3 (51.3–90.9)	REF 1.4 (0.57–3.4)	0.47	NI	NI
Yes	13 (36%)	57.7 (35.0–95.0)					52.7 (31.2–89.2)
Bone metastases (%) NA = 0
No	27 (75%)	82.7 (68.4–100)	REF 3.6 (1.1–11.5)	0.021	REF 1.5 (0.27–8.6)	0.62	77.1 (62.5–95.1)	REF 6.7 (2.4–19.2)	<0.0001	REF 6.4 (1.5–26.8)	0.011
Yes	9 (25%)	41.7 (18.5–94.0)					14.8 (2.6–86.0)
NLR, NA = 4
<3	18 (56%)	100 (100–100)	REF 19.4 (2.2–170.7)	0.0075	REF 16.7 (1.8–156.6)	0.014	88.1 (73.9–100)	REF 3.3 (1.2–9.4)	0.026	REF 2.5 (0.79–7.9)	0.12
≥3	14 (44%)	50.0 (27.2–91.9)					48.2 (27.6–84.3)

CI: confidence interval; HR: hazard ratio; NA: not available; NI: not indicated; NLR: Neutrophils-to-lymphocytes ratio; OS: overall survival; PFS: progression-free survival; PS: performance status; RCC: renal cell carcinoma; REF: reference.